These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35943100)

  • 1. Hypertension and clinical outcomes in patients with familial hypercholesterolemia.
    Liu MM; Peng J; Xu RX; Guo YL; Zhu CG; Wu NQ; Li JJ
    J Hypertens; 2022 Sep; 40(9):1713-1721. PubMed ID: 35943100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of diabetes on coronary severity and cardiovascular outcomes in patients with heterozygous familial hypercholesterolaemia.
    Liu MM; Peng J; Guo YL; Wu NQ; Zhu CG; Gao Y; Dong Q; Li JJ
    Eur J Prev Cardiol; 2022 Jan; 28(16):1807-1816. PubMed ID: 33778872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relations of physical signs to genotype, lipid and inflammatory markers, coronary stenosis or calcification, and outcomes in patients with heterozygous familial hypercholesterolemia.
    Liu MM; Peng J; Guo YL; Zhu CG; Wu NQ; Xu RX; Dong Q; Li JJ
    J Transl Med; 2021 Dec; 19(1):498. PubMed ID: 34876165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in phenotype, genotype and cardiovascular events between patients with probable and definite heterozygous familial hypercholesterolemia.
    Cao YX; Zhou BY; Sun D; Li S; Guo YL; Zhu CG; Wu NQ; Gao Y; Xu RX; Liu G; Dong Q; Li JJ
    Per Med; 2019 Nov; 16(6):467-478. PubMed ID: 31691639
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasma proprotein convertase subtilisin/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia.
    Cao YX; Liu HH; Jin JL; Sun D; Guo YL; Wu NQ; Zhu CG; Xu RX; Sun J; Santos RD; Li JJ
    Eur J Prev Cardiol; 2021 Apr; 28(3):272-279. PubMed ID: 33891693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and genetic characteristics of familial hypercholesterolemia patients with type 2 diabetes.
    Sun D; Cao YX; You XD; Zhou BY; Li S; Guo YL; Zhang Y; Wu NQ; Zhu CG; Gao Y; Dong QT; Liu G; Dong Q; Li JJ
    J Endocrinol Invest; 2019 May; 42(5):591-598. PubMed ID: 30276670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and genetic differences between heterozygous familial hypercholesterolemia patients with and without type 2 diabetes.
    Climent E; Pérez-Calahorra S; Benaiges D; Pintó X; Suárez-Tembra M; Plana N; Sánchez-Hernández RM; Valdivielso P; Ascaso JF; Pedro-Botet J
    Rev Esp Cardiol (Engl Ed); 2020 Sep; 73(9):718-724. PubMed ID: 31672559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of heterozygous familial hypercholesterolemia and combined hyperlipidemia phenotype in very young survivors of myocardial infarction and their association with the severity of atheromatous burden.
    Rallidis LS; Kosmas N; Tsirebolos G; Rallidi M; Kiouri E; Kalpakos D
    J Clin Lipidol; 2019; 13(3):502-508. PubMed ID: 30956097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial hypercholesterolemia among unselected contemporary patients presenting with first myocardial infarction: Prevalence, risk factor burden, and impact on age at presentation.
    Mortensen MB; Kulenovic I; Klausen IC; Falk E
    J Clin Lipidol; 2016; 10(5):1145-1152.e1. PubMed ID: 27678431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease.
    Jin JL; Zhang HW; Cao YX; Liu HH; Hua Q; Li YF; Zhang Y; Guo YL; Wu NQ; Zhu CG; Xu RX; Gao Y; Cui CJ; Liu G; Sun J; Dong Q; Li JJ
    Hepatol Int; 2021 Apr; 15(2):413-423. PubMed ID: 33740211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of long-term outcomes of young patients after a coronary event associated with familial hypercholesterolemia.
    Wang X; Cai G; Wang Y; Liu R; Xi Z; Li G; Wen W; Wu Y; Wang C; Ji Q; Wang X; Zhang Q; Zeng Y; Wang L; Liu W; Zhou Y
    Lipids Health Dis; 2019 Jun; 18(1):131. PubMed ID: 31153370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia.
    Gallo A; Pérez de Isla L; Charrière S; Vimont A; Alonso R; Muñiz-Grijalvo O; Díaz-Díaz JL; Zambón D; Moulin P; Bruckert E; Mata P; Béliard S;
    JACC Cardiovasc Imaging; 2021 Dec; 14(12):2414-2424. PubMed ID: 34274263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline and on-statin treatment lipoprotein(a) levels for predicting cardiovascular events in patients with familial hypercholesterolemia.
    Cao YX; Jin JL; Guo YL; Sun D; Liu HH; Wu NQ; Xu RX; Zhu CG; Liu G; Dong Q; Sun J; Li JJ
    Atherosclerosis; 2019 Dec; 291():27-33. PubMed ID: 31683090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels.
    Funabashi S; Kataoka Y; Hori M; Ogura M; Doi T; Noguchi T; Harada-Shiba M
    J Am Heart Assoc; 2022 Aug; 11(16):e025232. PubMed ID: 35929461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updates on the Use of Subclinical Atherosclerosis to Predict Risk of Cardiovascular Events in Heterozygous Familial Hypercholesterolemia.
    Gallo A; Mszar R; Miname MH
    Curr Atheroscler Rep; 2022 Jun; 24(6):407-418. PubMed ID: 35386094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of small dense LDL-cholesterol with disease severity, hypertension status and clinical outcome in patients with coronary artery disease.
    Zhang HW; Jin JL; Cao YX; Liu HH; Zhang Y; Guo YL; Wu NQ; Zhu CG; Gao Y; Xu RX; Hua Q; Li YF; Cui CJ; Dong Q; Sun J; Li JJ
    J Hypertens; 2021 Mar; 39(3):511-518. PubMed ID: 33186323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early coronary calcifications are related to cholesterol burden in heterozygous familial hypercholesterolemia.
    Gallo A; Giral P; Carrié A; Carreau V; Béliard S; Bittar R; Maranghi M; Arca M; Cluzel P; Redheuil A; Bruckert E; Rosenbaum D
    J Clin Lipidol; 2017; 11(3):704-711.e2. PubMed ID: 28456681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronary computed tomographic angiographic findings in asymptomatic patients with heterozygous familial hypercholesterolemia and null allele low-density lipoprotein receptor mutations.
    Viladés Medel D; Leta Petracca R; Carreras Costa F; Cardona Olle M; Barros Membrilla A; Hidalgo Perez JA; Pujadas Olano S; Alomar Serrallach X; Franco Peral M; Pons-Lladó G
    Am J Cardiol; 2013 Apr; 111(7):955-61. PubMed ID: 23340035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Heterozygous familial hypercholesterolemia: the first challenge for anti-PCSK9 monoclonal antibodies].
    Zambon A
    G Ital Cardiol (Rome); 2016 Apr; 17(4 Suppl 1):22S-30. PubMed ID: 27312020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein(a) level associates with coronary artery disease rather than carotid lesions in patients with familial hypercholesterolemia.
    Sun D; Zhou BY; Zhao X; Li S; Zhu CG; Guo YL; Gao Y; Wu NQ; Liu G; Dong Q; Li JJ
    J Clin Lab Anal; 2018 Sep; 32(7):e22442. PubMed ID: 29603377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.